来苏之望丨张小田教授：创新靶向联合免疫，有望攻下晚期胃癌治疗“堡垒”( 三 )
参考资料：
[1] Shen L, Lu M, Chen ZD, et al. Phase II trial of surufatinib plus toripalimabfor disease progression after first-line chemotherapy with platinum and fluoropyrimidine in advanced gastric or gastroesophageal junctionadenocarcinoma.2021 ASCO. e16040.
[2] MoehlerM., Shitara K., Garrido M. LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo)versus chemo as first-line (1L) treatment for advanced gastriccancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma(EAC): first results of the CheckMate 649 study. Ann Oncol. 2020;31:S1191.
[3] FukuokaS, Hara H, Takahashi N, et al. Regorafenib Plus Nivolumab in Patients WithAdvanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, andDose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). J Clin Oncol. 2020 Jun20;38(18):2053-2061.
[4] Lu M,Cao YS, Gong JF,et al. A Phase I Trial of Surufatinib plus Toripalimab inPatients with Advanced Solid Tumor. AACR 2020. Abstract No. 9563.
*此文仅用于向医学人士提供科学信息 ， 不代表本平台观点
【来苏之望丨张小田教授：创新靶向联合免疫，有望攻下晚期胃癌治疗“堡垒”】
推荐阅读
- EHA中国之声丨张磊教授：我国儿童ET的现状及特点，一项真实世界研究
- 来苏之望|中国“核”心大咖共话甲状腺癌诊疗现状，民族药物谱写临床治疗新格局
- 中国队|突发官宣3连！叙利亚5大原则不来苏州，主动改赛死磕中国队，补招2人
- 篮网队|巴萨颤抖吗？马竞帝星：感谢巴萨送来苏神，我们的大门已向梅西敞开！